Cannabis use disorder affects up to 42% of individuals with schizophrenia, correlating with earlier onset, increased positive symptoms, and more frequent hospitalizations. This study employed an untargeted lipidomics approach to identify biomarkers in plasma samples from subjects with schizophrenia, cannabis use disorder, or both (dual diagnosis), aiming to elucidate the … [Read more...] about Uncovering metabolic dysregulation in schizophrenia and cannabis use disorder through untargeted plasma lipidomics
science
Yale digs into the science of cannabis
As states nationwide legalize the sale of cannabis, a new Yale center led by Deepak Cyril D’Souza will study its effects on the brain and mental health. As many U.S. states adopt policies that legalize the commercialization of cannabis, Yale School of Medicine recently announced the creation of the new Yale Center for the Science of Cannabis and Cannabinoids, which will … [Read more...] about Yale digs into the science of cannabis
